EHSF
The European Hidradenitis Suppurativa Foundation (EHSF) is a non-profit, public benefit organisation, which aims to raise funds for the promotion of research and public health care in the field of hidradenitis suppurativa (HS). The organisation encourages innovation in HS therapies to improve patient care and help to overcome the psychological burden of this immune disease.
The EHSF holds annual conferences. Click the links below to view further information about EHSF events on Medthority, including congress highlights.
How do I register for the upcoming EHSF Conference?
You can find information on upcoming and past EHSF events at the links further down this page. Can’t see next year’s event yet? Keep an eye out for information coming soon!
Looking for resources on HS?
Advances in HS
EHSF 2024: Surgical updates and changes to practice
Expert insights on CSU management
The latest in CSU diagnosis and care
Alopecia areata: Progressing practice
Latest treatment options and patient insights
Atopic Dermatitis Learning Zone
Welcome to the Atopic Dermatitis Learning Zone, an educational resource, intended for healthcare professionals, that provides credible medical information on the epidemiology, pathophysiology and burden of atopic dermatitis, as well as diagnostic techniques, treatment regimens and guideline recommendations.
Improving Treatment Options for Childhood Psoriasis
This Learning Zone introduces you to our young patient Mia who, along with our paediatric psoriasis experts, helps us to describe the burden of childhood psoriasis for patients and their families, particularly the difficulties around diagnosis, comorbidities and limited treatment options.
Psoriasis Academy
When it comes to psoriasis, a knowledgeable healthcare professional is highly valued by patients (Pariser et al., 2016). With this in mind, we created The Psoriasis Academy, an online hub featuring succinct and easily accessible information for all healthcare professionals who want to know more about psoriasis and keep up to date with the latest developments.